BeiGene's Tevimbra Approved by FDA for Second-Line Treatment of Esophageal Squamous Cell Carcinoma, Demonstrates Survival Improvement
FDA Approval Scope and Drug Characteristics
On March 13, 2024, the U.S. FDA approved BeiGene's Tevimbra (tislelizumab-jsgr) as a monotherapy for adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who have progressed after prior systemic chemotherapy and have no prior PD-1/PD-L1 inhibitor treatment history. Tevimbra is a humanized IgG4 monoclonal antibody that blocks programmed cell death protein-1 (PD-1), designed to minimize binding to macrophage Fc gamma receptors. This decision marks the transition from Phase 3 clinical development to approval and commercialization, with the U.S. dosing regimen being 200mg intravenous infusion every three weeks.
Survival Benefit Confirmed in Phase 3 Trial
The approval was based on the global Phase 3 RATIONALE-302 (NCT03430843) trial, which randomly assigned 512 previously treated patients 1:1 to Tevimbra or investigator-selected chemotherapy. The median overall survival was 8.6 months for Tevimbra and 6.3 months for the paclitaxel, docetaxel, or irinotecan chemotherapy group, with a hazard ratio of 0.70 (95% confidence interval 0.57–0.85). The study, which enrolled patients regardless of PD-L1 expression, showed a 30% reduction in risk of death, reinforcing its clinical value as a second-line PD-1 monotherapy without the need for biomarker selection.
Competitive Landscape and Regulatory History
Direct competitors in the same treatment line include Bristol-Myers Squibb's (BMY) Opdivo (nivolumab, PD-1), while Merck's (MRK) Keytruda (pembrolizumab, PD-1) is a prior-line immunotherapy used in patients with PD-L1 CPS ≥10. In first-line treatment, combinations of Opdivo with chemotherapy, Opdivo with Yervoy (ipilimumab, CTLA-4), and Keytruda with chemotherapy have already established a treatment paradigm, limiting the pool of subsequent patients to those with prior PD-1 treatment experience. The European Union approved Tevimbra for ESCC on September 15, 2023, and Japan's Ministry of Health, Labour and Welfare on March 27, 2025. In the U.S., the original BLA was approved without an FDA Oncologic Drugs Advisory Committee vote, based on the FDA's determination that there were no significant public health concerns.
Commercial Performance and Company Value
The global esophageal cancer treatment market was estimated at approximately USD 2.90 billion in 2024 and is projected to grow to USD 7.91 billion by 2035, with immunotherapies as a key driver. Tevimbra's global revenue is expected to increase from USD 620.8 million in 2024 to USD 737.3 million in 2025, a 18.8% growth, demonstrating its value as a multi-regional, multi-tumor type commercial asset. However, in the U.S. second-line ESCC market, the expansion of first-line PD-1 combination therapies may reduce the number of eligible patients, shifting BeiGene's revenue leverage to subsequent first-line ESCC and gastric/gastroesophageal junction cancer indications.
BeiGene (ONC) has transitioned Tevimbra into an FDA-approved and commercially available PD-1 asset by achieving an 8.6-month overall survival and a hazard ratio of 0.70 in the Phase 3 RATIONALE-302 trial. In the short term, it will enter the ESCC immunotherapy market established by Opdivo (nivolumab) and Keytruda (pembrolizumab), but the expansion of first-line PD-1 combination therapies limits the approved second-line patient population. Mid- to long-term value will be determined by the USD 2.90 billion global esophageal cancer treatment market in 2024 and additional first-line and gastric cancer indications. The PD-L1 non-selective survival improvement data provides a basis for research on patient selection and treatment sequencing, while the USD 737.3 million revenue and 18.8% growth rate in 2025 demonstrate global commercial execution capability to the industry.
Source: openFDA (api_fda)
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=BLA761232